What’s new with DiaSorin Molecular.

Available here is a selection of our latest news about DiaSorin Molecular.
Filter by year
Published on 21 Sep 2017

Extended CE-IVD Certification Expands Sample Claim for DiaSorin Molecular’s Simplexa HSV 1 & 2 Kit

DiaSorin Molecular, LLC announced today that the company has earned CE-IVD certification extending the sample claims for its Simplexa HSV 1 & 2 Direct Assay. The certification adds – cutaneous and mucocutaneous lesion swabs – to previously cleared specimen types of cerebrospinal fluid (CSF) and genital lesion swabs.

DiaSorin Molecular
Published on 12 Sep 2017

DiaSorin Molecular Receives FDA Clearance for Reliable C. difficile Assay on LIAISON® MDX Platform

DiaSorin Molecular today announced the U.S. introduction of the SimplexaTM C. difficile Direct Assay, upon receiving clearance from the Food and Drug Administration.

The new assay runs on the company’s LIAISON® MDX system, a scalable benchtop PCR instrument that delivers qualitative and quantitative, sample-to-answer, multi-analyte results. The Simplexa assay detects the Clostridium difficile toxin B gene (tcdB), present in liquid or unformed stool samples, aiding in the diagnosis of C. difficile infection.

DiaSorin Molecular
Published on 10 Jul 2017

DiaSorin Molecular launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP.

DiaSorin Molecular launches a new CE-IVD molecular diagnostic test, Iam CBFB-MYH11 (not available in the USA) for the ultra-rapid identification of one of the most common genetic causes of Acute Myeloid Leukemia (AML). This new early diagnosis will aid effective stratification of patient risk, facilitating timely and effective implementation of therapy for patient management improvement.

DiaSorin Molecular


The upcoming events we are going to take part in.

Discover our Events